Lyell Immunopharma (LYEL) Times Interest Earned (2020 - 2026)
Lyell Immunopharma (LYEL) posted Times Interest Earned of -$0.75 for Q1 2026, up 89.91% sequentially from -$7.47 in Q4 2025, and up 6.18% YoY from -$0.71 in Q1 2025.
Lyell Immunopharma (LYEL) Times Interest Earned (2020 - 2026) Analysis & Trends
Lyell Immunopharma has reported Times Interest Earned for 7 years, with the latest figure at -$0.75 in Q1 2026.
- Quarterly Times Interest Earned rose 6.18% year-over-year to -$0.75 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$4.37 (up 13.56% YoY) and the FY2025 annual result came in at -$15.76, down 1479.39% from the prior year.
- Times Interest Earned rose to -$0.75 in Q1 2026 per LYEL's latest filing, from -$7.47 in the prior quarter.
- Over five years, Times Interest Earned peaked at -$0.24 in Q4 2023 and troughed at -$12.63 in Q4 2022.
- A 5-year average of -$2.32 and a median of -$0.69 in 2025 frame the typical range for Times Interest Earned.
- The sharpest annual moves came in 2022 and 2023: Times Interest Earned tumbled 3278.86% in 2022, then surged 98.1% in 2023.
- Over 5 years, Times Interest Earned stood at -$12.63 in 2022, then soared by 98.1% to -$0.24 in 2023, then plunged by 133.61% to -$0.56 in 2024, then slumped by 1234.66% to -$7.47 in 2025, then soared by 89.91% to -$0.75 in 2026.
- According to Business Quant data, Times Interest Earned over the past three periods registered -$0.75, -$7.47, and -$0.57 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Lyell Immunopharma | 326.39 Mn | 326.39 Mn | - | -0.85 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -0.85 |
| Mar 31, 2026 | -0.75 |
| Dec 31, 2025 | -7.47 |
| Sep 30, 2025 | -0.57 |
| Jun 30, 2025 | -0.69 |
| Mar 31, 2025 | -0.80 |
| Dec 31, 2024 | -0.56 |
| Sep 30, 2024 | -0.67 |
| Jun 30, 2024 | -0.66 |
| Mar 31, 2024 | -2.92 |
| Dec 31, 2023 | -0.24 |
| Sep 30, 2023 | -4.84 |
| Jun 30, 2023 | -2.50 |
| Mar 31, 2023 | -2.56 |
| Dec 31, 2022 | -12.63 |
| Sep 30, 2022 | -0.55 |
| Jun 30, 2022 | -0.41 |
| Mar 31, 2022 | -0.67 |
| Dec 31, 2021 | -0.37 |
| Sep 30, 2021 | -4.33 |